Filter posts

BIO CEO 2012 Opening Remarks

The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at …

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel …

Fireside Chat with Dr. Mikael Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat …

Picks and Pans – The Buy-Side View for 2012

What’s the forecast for biotech in 2012? Do investors think it is a good time …

“Alz” Well That Ends Well: The Beta-Amyloid Debate in Alzheimer’s Research

Researchers and clinicians alike believe there is substantial evidence to support the hypothesis that Alzheimer’s …

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO …

BIO CEO Company Snapshot: ImmunoGen, Inc.

In the latest Company Snapshot for the 2012 BIO CEO & Investor Conference in New …

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second …

Where's the Deal?

With only two weeks to go in 2011 it is looking like a five year …

BIO CEO Company Snapshot: NuPathe Inc.

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & …